Virax Biolabs Group Limited announced that it has signed a Purchase Order with Cosmos Health (Cosmos) to launch and market COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits. Pursuant to their previously signed distribution agreement dated September 2022, Cosmos will have exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the ViraxClear branded test kits across Europe on a non-exclusive basis. The COVID-19 & Influenza A+B antigen combo rapid test is a single-use test kit intended for qualitative detection of nucleocapsid protein antigen of Influenza A and B viral antigens and COVID-19 antigen from nasal swab specimens.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8395 USD | +7.13% | +21.67% | -42.50% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
0.8395 USD | +7.13% | +21.67% | 1.85M | ||
0.692 USD | -1.15% | +1.76% | 11.79M | ||
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-42.50% | 1.85M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- VRAX Stock
- News Virax Biolabs Group Limited
- Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health